Johnson & Johnson will spend $16.6 billion to buy cardiovascular technology company Abiomed to strengthen its medical device division.The health care giant said Tuesday that it will pay $380 for each ...

Please provide your email address to receive an email when new articles are posted on . The European and UK markets will have access to the CLAiR technology from Toku. CLAiR assesses cardiovascular ...

Cardiovascular disease is the world’s top killer, claiming over 20.5 million lives in 2021, according to the World Heart ...

New solutions for improving and managing cardiovascular health are urgently needed, but effective and worthwhile solutions often fail to make it to patients because all critical stakeholders are not ...

Here, five cardiology leaders weigh in on the possibilities of ending cardiovascular disease: Gopi Dandamudi, MD. Executive Medical Director of the Center for Cardiovascular Health at Virginia Mason ...

Major Insurer Joins UnitedHealthcare in Covering Cleerly's AI-QCT/AI-CPA Technology, Expanding Access to 61 Million Americans With more than 16 million covered lives, Cigna joins UnitedHealthcare and ...

From 2001 to 2019, there was an increase in cardiovascular-related complications during pregnancy, according to a recent study.

One person dies of cardiovascular disease (CVD) every 34 seconds in the U.S., making it the nation’s leading cause of death. This chronic condition affects roughly 127.9 million Americans, and from ...

(AP) - Johnson & Johnson is spending more than $16 billion to move deeper into treating heart disease and continue a shift started last year away from its consumer health roots. The health care giant ...

Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome ...

Remedy Robotics has joined forces with the Australian Stroke Alliance for introducing endovascular care to hospitals in the ...